Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Capital Lease Obligations

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Capital Lease Obligations

NAUT · NASDAQ
CompanyCapital Lease Obligations
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
26.97M
12.7%2.5%N/A
20.78M
-11.7%28.0%N/A
0.00
N/AN/AN/A
3.43M
-8.4%-8.6%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
11.26M
-48.0%-24.1%34.1%
195.00K
-34.5%N/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58